GCP
OPNT

GSA Capital Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

GSA Capital Partners’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,110
Closed -$203K – 1715
2020
Q3 		$203K Buy
27,110
+13,583
+100% +$121K 0.03% 1006
2020
Q2 		$122K Buy
+13,527
New +$140K 0.07% 448

Other funds holding OPNT

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's OPNT Position: Q4 2020 in Review

GSA Capital Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2020, closing a stake of 27,110 shares — an estimated $203K sold.

GSA Capital Partners first reported a position in OPNT in Q2 2020 and held it in 2 quarters. The position peaked at $203K in Q3 2020. 29 funds tracked by Wall St. Rank hold OPNT as of Q4 2020.

  • GSA Capital Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • GSA Capital Partners sold 27,110 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $203K.
  • GSA Capital Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • GSA Capital Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $203K in Q3 2020.
  • 29 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on GSA Capital Partners's 13F filing for Q4 2020, filed 3 Feb 2021.